Medicines Optimisation Team Standard Operating procedure for Alogliptin Audit:
|
|
- Andrew Bradford
- 5 years ago
- Views:
Transcription
1 Medicines Optimisation Team Standard Operating procedure for Alogliptin Audit: To review type 2 diabetic patients prescribed dipedtidylpeptidase-4 (DPP-4) inhibitors (linagliptin (Trajenta, saxagliptin (Onglyza ), sitagliptin (Januvia ), vildagliptin (Galvus, to determine continued need for prescribing or if appropriate, change therapy to the most cost-effective option, alogliptin. Aim Whilst combination products are not on the formulary, some patients for clinical reason are prescribed these products. This audit will also review patients prescribed DPP-4 inhibitors and metformin combination products to change to a more cost-effective alogliptin and metformin combination. Rationale 1. Alogliptin (Vipidia ) is available as 6.25mg, 12.5mg and, 25mg tablets and is the first line option for DPP-4 inhibitor on the formulary. It is licensed for: o Dual therapy in combination with metformin, a thiazolidinedione, a or o Triple therapy in combination with metformin and sulfonylurea, or o Triple therapy with metformin and a thiazolidinedione or insulin. sulfonylurea or insulin 2. Alogliptin when prescribed on FP10 prescription is 20% lower than other DPP-4- inhibitors. It is worth noting that all DPP-4 inhibitors have a flat pricing structure across strengths and therefore doses should be optimised to the fewest number of tablets taken. See Table Whilst there is no head to head trials comparing DPP-4 inhibitors, NICE, MTRAC and PrescQIPP recommend that (1): o The gliptin with the lowest acquisition cost should be used. o Within licence, gliptins should only be continued if there has been a beneficial metabolic response i.e a reduction by at least 5.5mmol/mol or (0.5%) points in HbA1c in 6 months after initiation. 4. Safety o Alogliptin appeared well tolerated in the two RCTs reviewed within the NICE evidence summary, with most adverse events reported to be of mild or moderate intensity (1). o Due to the increased risk of hypoglycaemia in combination with a sulfonylurea (SU), insulin or combination therapy with thiazolidinedione plus metformin, a lower dose of these medications should be considered to reduce the risk of hypoglycaemia when these medicinal products are used in combination with alogliptin as indicated in the product license.(3) o Dose reductions are needed in patients with renal (3)- refer to Table 1 for 1 P a g e
2 specific doses. o Alogliptin is not recommended for use in patients with severe hepatic (3). o There is limited experience of alogliptin use in clinical trials in patients with congestive heart failure of New York Heart Association (NYHA) functional class III IV. Use is not recommended in these patients(3). o Like the other DPP-4 inhibitors no dosage adjustment is required for elderly ( 65 years) based solely on age. Also like the other DPP-4 inhibitors, experience in patients aged 75 years and older is very limited and caution should be exercised when treating this population. 3 o Acute pancreatitis Like other DPP-4 inhibitors, alogliptin also has a potential risk of developing acute pancreatitis. In most cases, pancreatitis resolved after discontinuation of treatment. The MHRA advises that patients should be informed of the characteristic symptom of acute pancreatitis. If pancreatitis is suspected, alogliptin should be discontinued; if acute pancreatitis is confirmed, alogliptin should not be restarted(4). o Cardiovascular safety Although newer glucose-lowering drugs are effective at reducinghba1c levels, they all lack robust clinical outcome data, particularly around their cardiovascular effects and long-term safety in people with Type-2 diabetes. Improvements in surrogate markers (including HbA1c levels) do not automatically confer benefits on mortality or morbidity, and risks may become apparent only over time when these agents have more widespread use in a diverse population. In 2016 FDA, issued updated warnings on the use of saxagliptan and alogliptin potentially causing heart failure. These have been recently reviewed by UKMI and have concluded that heart failure was not the primary outcome being measured and the numbers were small and the data unreliable to be conclusive from the reporting trials. Also, there is no indication to date 01/10/16 that MHRA or EMA consider that any additional warning is necessary for DPP-4 inhibitors as a group or saxagliptin or alogliptin individually. For present it would be sensible to use the DDP-4 inhibitors of choice and observe the warnings and cautions of the respective SPC and prescribe within the licensed indications. Audit criteria Inclusion criteria All patients on the following list of drugs for the management of type 2 diabetes: o Linagliptin (Trajenta ) o Linagliptin & metformin hydrochloride (Jentadueto ) o Saxagliptin (Onglyza ) o Saxagliptin & metformin hydrochloride (Komboglyze ) o Sitagliptin (Januvia ) o Sitagliptin & metformin hydrochloride (Janumet ) o Vildagliptin (Galvus ) 2 P a g e
3 Exclusion criteria o Vildagliptin & metformin hydrochloride (Eucreas ) o Patients prescribed a gliptin as monotherapy, as alogliptin is unlicensed for monotherapy o Patients prescribed a gliptin for type 1 diabetes as this is unlicensed use of the drug. o Patients with previous intolerance to alogliptin o Previous treatment failure with alogliptin o Patients who have been taking a gliptin for more than 6 months but have not achieved the required reduction of more than 5-6 mmols in HbA1c or achieved their individualised target these patients should be flagged to the GP for review. Please note that the new NICE guidelines discusses individualised care and targets are based on case by case, so review should be based on what has been set for patients. o Patients with heart failure of NYHA class III-IV o Patients who do not have a recent assessment of their renal function in the last 12 months these patients should be identified for the practice to call in for new urea, electrolytes, creatinine and EGFR prior to commencing the switch. o Patients who have rapidly declining renal function or an EGFR less than 30ml/min would be more preferable to be on linaglitpin as this requires no dosage adjustment for renal failure. o Patients who are having renal dialysis or peritoneal dialysis would be preferable to be on linagliptin as it is not expected to be eliminated to a therapeutically significant degree by dialysis. o Patients with severe hepatic (Child-Pugh score >9) o Patients under the age of 18 years o Patients who are pregnant o Patients who are currently breast feeding o Documented intolerance to any of the excipients listed in the SPC o Patients with a history of pancreatitis o Caution for patients >75yrs, no data on adjustment of dose on this population 3 P a g e
4 Method 1. A local agreement should be made at the practice with practice pharmacist to define the process for the dosage switch. 2. A practice based search should be made to determine the eligible patients for the switch based on the inclusion and exclusion criteria above 3. Undertake clinical audit taking into consideration, renal, hepatic and dose equivalence- refer to Table 1 and 2 4. Consent should be obtained from the prescriber of audit results and recommendations before any changes are made to the patient s medication records and prescribed medicines. 5. Ensure that the DPP-4 inhibitor has reduced HbA1c by 5.5mmol/l (0.5%) over 6 months. If criteria has been met consider a switch as below. If criteria has not been met, this needs to be highlighted to practices to review therapy. 6. Reduce dosage in renal as per table 1 and 2. o Reduce dose to 12.5mg daily if creatinine clearance 30 to 50 ml/min. o Reduce dose to 6.25mg daily if creatinine clearance < 30 ml/min. 7. For Patients on Dual Therapy ( Look at Table 1 to consider dosing equivalence ) o In combination with metformin: Consider alogliptin an alternative to sitagliptin or vildagliptin or linagliptin or saxagliptin. o In combination with sulphonylurea : Consider alogliptin an alternative to sitagliptin or vildagliptin or saxagliptin. o In combination with pioglitazone: Consider alogliptin an alternative to sitagliptin or vildagliptin or saxagliptin. o In combination with insulin :Consider alogliptin as an alternative to sitagliptin or vildagliptin or linagliptin or saxagliptin. 5. For Patient on Triple Therapy o In combination with metformin and pioglitazone: Consider alogliptin as an alternative to sitagliptin in combination with metformin and pioglitazone. o In combination with metformin and SU: Consider alogliptin as an alternative to sitagliptin in combination with metformin and SU o In combination with metformin and insulin : Consider alogliptin as an alternative to sitagliptin or vildagliptin or linagliptin or saxagliptin. 6. For patients on DPP-4 inhibitors/metformin combination products 4 P a g e
5 o Combination products are not on the formulary, but if patients are on a gliptin and metformin combination for a specific therapeutic reason and are stable, there is potential for optimisation to review to the most cost effective alogliptin/metformin combination. See Table 2 below for cost comparison. It is left to the clinical discretion of the pharmacist to implement this change. Please see Table 3 for cost comparison of combination products Notes for Practice Pharmacist/ nurse/gp: Ensure that patients who are switched are followed up to review diabetic control and side effects, with recheck of HbA1c in 8-12 weeks. Advise patients who are on insulin to monitor their blood glucose levels and to be vigilant for any changes in levels, particularly hypoglycaemia. Before implementation, liaise with local community pharmacies t to inform in advance of change and also to maximise their opportunity to counsel and offer patients the New Medicines Review (NMS) service. References: 1. PresQiPP Bulletin 78,Alogliptin Nov 2014 Version FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin 3. Summary of Product Characteristics. Vipidia 6.25mg, 12.5mg, 25mg tablets (alogliptin). Takeda UK Ltd. Last updated 13/1/14. Available from 4. MHRA Drug safety update. Dipeptidylpeptidase-4 inhibitors ( gliptins ): risk of acute pancreatitis.september2012.available via 5 P a g e
6 Appendix 1 data collection form See attached data collection sheet. Date completed: <insert date> 6 P a g e
7 +metformin + sulfonylurea + pioglitazone + metformin + sulfonylurea + metformin + pioglitazone Table 1: DPP-4 licence comparisons and costs (1) Dual therapy Triple therapy Renal (egfr Drug Strengths Doses (maximal or usual) 28 day cost Monotherapy Addition to insulin ml/min/1.73m 2 ) Mild Moderate Severe Hepatic ESRD Sitagliptin 25mg 50mg 100mg 100mg daily Yes Yes Yes Yes Yes Yes Yes +/- only metformin Moderate -50mg daily Severe to ESRD -25mg daily Use cautiously in severe hepatic Vildagliptin 50mg 50mg twice daily Yes Yes Yes Yes Yes No Yes +/- only metformin Moderate to severe -50mg daily ESRD not recommended Not recommended Linagliptin 5mg 5mg daily Yes Yes No No Yes No Yes +/- only metformin No dosage adjustment No reduction but limited experience Saxagliptin 2.5mg 5mg 5mg daily Yes Yes Yes Yes Yes No Yes +/- only metformin Moderate to severe - 2.5mg daily ESRD not recommended Not recommended in severe hepatic 7 P a g e
8 Alogliptin 6.25mg 12.5mg 25mg 25mg daily No Yes Yes Yes Limited data Yes Yes +/- only metformin Moderate 12.5mg daily Severe to ESRD mg daily Not recommended in severe hepatic No dosage adjustment is recommended in elderly patients solely based on age; however caution needed in this population. Refer to the SPCs for complete information. Table 2 : Dose Equivalence Summary Table of DPP-4 inhibitors /renal Renal Function Alogliptin Linagliptin Saxgliptin Sitagliptin Vildagliptin Normal 25mg OD 5mg OD 5mg OD 100mg OD 50mg BD (or 50mg OD with an SU) Mild renal 25mg OD 5mg OD 5mg OD 100mg OD 50mg BD (or 50mg OD with an SU) Moderate renal 12.5mg OD 5mg OD 2.5mg OD 50mg OD 50mg OD Severe renal 6.25mg OD 5mg OD 2.5mg OD 25mg OD 50mg OD End stage renal disease 6.25mg OD 5mg OD Not recommended 25mg OD Not recommended requiring dialysis Hepatic Not recommended in severe hepatic No dose adjustment required for mild to moderate hepatic No reduction but limited experience Use with caution in patients with moderate hepatic but no dose No dose adjustment required for mild to moderate hepatic Chronic kidney disease in adults: UK guidelines for identification, management and referral (March 2006) define renal function as follows: Not recommended 8 P a g e
9 Degree of egfr ml/minute/1.73 m 2 Normal - Stage 1 Mild - Stage 2 More than 90 (with other evidence of kidney damage) (with other evidence of kidney damage) Moderate 1 - Stage Severe - Stage Established renal failure - Stage 5 Less than 15 NICE clinical guideline 73 (September 2008) Chronic kidney disease: Stage 3A egfr 45-59, Stage 3B egfr Table 3 Cost comparison of Combination DPP-4 inhibitor/metformin DPP-4 combination Dose Cost for 56 tablets ( ) Alogliptin 12.5mg plus metformin 1000mg (Vipdomet ) 1 twice daily Sitagliptin 50mg plus metformin 1000mg (Janumet ) 1 twice daily Vildagliptin 50mg plus metformin 850mg (Eucreas ) Vildagliptin 50mg plus metformin 1000mg (Eucreas ) Saxagliptin 2.5mg plus metformin 850mg (Komboglyze ) Saxagliptin 2.5mg plus metformin 1000mg (Komboglyze ) Linagliptin 2.5mg plus metformin 850mg (Jentadueto ) Linagliptin 2.5mg plus metformin 1000mg (Jentadueto ) 1 twice daily twice daily twice daily P a g e
10 Appendix 1 Patient letter Date as Postmark Title Initial Last Name Home Full Address (stacked) Dear Calling Name IMPORTANT INFORMATION As a practice we regularly review prescribing to ensure patients are on appropriate treatments in line with national guidance. We are currently reviewing patients prescribed a group of drugs called gliptins. Gliptins are a recent addition to the types of drugs used to lower blood glucose in type 2 diabetes and are usually added to existing treatments if these are not effective enough on their own. There are a number of different gliptins available. They all work in a similar way and have similar side- effects. According to currently available evidence, no single gliptin has been shown to be more effective than the others. We are therefore changing your current gliptin to an equivalent strength of a gliptpin called alogliptin. Alogliptin represents the best value for money for the NHS compared to the other gliptins. The money saved by prescribing alogliptin can then be used to contribute toward other NHS services. When you next request your medication, you will notice the following change. Old Prescription Drug: Strength: New Prescription Drug: Strength: Dose: Dose: Frequency: Frequency: We have arranged an appointment for you to have a blood test to check your HB1ac in 12 weeks time which will allow us to assess your diabetic control. The appointment will be on : at: If you can t make this appointment please call the practice to rearrange. Yours sincerely, On behalf of <Insert details 10 P a g e
11 Appendix 2 Patient letter alogliptin/metformin combination Date as Postmark Title Initial Last Name Home Full Address (stacked) Dear Calling Name IMPORTANT INFORMATION As a practice we regularly review prescribing to ensure patients are on appropriate treatments in line with national guidance. We are currently reviewing patients prescribed a group of drugs called gliptins. Gliptins are a recent addition to the types of drugs used to lower blood glucose in type 2 diabetes and are usually added to existing treatments if these are not effective enough on their own. Gliptins can be prescribed alone or in combination with another drug called metformin. There are a number of different gliptins/metformin combinations available, the preferred one based on quality and cost is alogliptin/metformin combination. They all work in a similar way and have similar side- effects. According to currently available evidence, no single gliptin/metformin has been shown to be more effective than the others. We are therefore changing your current gliptin/ metformin combination to an equivalent strength of alogliptin/metformin. Alogliptin represents the best value for money for the NHS compared to the other gliptins. The money saved by prescribing alogliptin/metformin can then be used to contribute toward other NHS services. When you next request your medication, you will notice the following change. Old Prescription Drug: Strength: New Prescription Drug: Strength: Dose: Dose: Frequency: Frequency: We have arranged an appointment for you to have a blood test to check your HB1ac in 12 weeks time which will allow us to assess your diabetic control. The appointment will be on : at: If you can t make this appointment please call the practice to rearrange. Yours sincerely, On behalf of <Insert details 11 P a g e
12 Document Change History Version Date Editor Details of significant changes 1.0 April 2017 Shaurna Reddy New Standard Template 2.0 January 2018 Thao Lam Addition of new licensing for triple therapy combinations for alogliptin Hb1ac follow up changed from 8 weeks to 12 weeks Head of Medicines Optimisation GP Prescribing Lead [Stafford and Surrounds CCG] Samantha Buckingham Dr Paddy Hanighan Date January 2018 Date January P a g e
Ref. Version Supersedes Approved for Date approved Document Owner N/A MMT 17/01/2017 Lois Taylor. Switching to Alogliptin (Vipidia )
Ref. Version Supersedes Approved for Date approved Document number use by Owner 001 1.0 N/A MMT 17/01/2017 Lois Taylor Aim: Switching to Alogliptin (Vipidia ) To reduce our spend on gliptins (DDP-4 drugs)
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More informationHave you seen a patient like Carol *?
(linagliptin) 5mg tablets Have you seen a patient like Carol *? *Hypothetical patient profile Carol * : 70 years old Retired schoolteacher *Hypothetical patient profile CAROL*: T2D patient with moderate
More informationPLEASE CHECK FULL SPECIFIC PRODUCT CHARACTERISTICS FOR MORE DETAILED AND CURRENT INFORMATION:
Metformin Standard tablets Modified-release tablets Metformin 1g sachets Metformin liquid 500mg/5ml (avoid use as expensive) < 2.00 5.32 for 56 tabs 500mg 13.16 for 60 sachets > 120 Ketoacidosis General
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationHave you seen a patient like Ronald *?
(linagliptin/metformin HCI) Have you seen a patient like Ronald *? *Hypothetical patient profile Ronald * : 70 years old Retired engineer *Hypothetical patient profile RONALD*: Metformin-uncontrolled T2D
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationAsacol / Mesalazine to Octasa Switch protocol
Asacol / Mesalazine to Octasa Switch protocol Applies to HaRD MMT Technicians, Pharmacists These protocols are produced by the NY&AWC MM team hosted by HaRD CCG for use by their employed MM team members.
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationGuideline for antihyperglycaemic therapy in adults with type 2 diabetes
Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin
More informationMetformin MR to low cost branded generic (Sukkarto SR) Switch Protocol
Metformin MR to low cost branded generic (Sukkarto SR) Switch Protocol Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols are produced by the NY&AWC MM team
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 VELMETIA 50 mg/850 mg, film-coated tablets B/56 (CIP code: 386 778-0) VELMETIA 50 mg/1 000 mg, film-coated
More informationCONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients
Galvus PRESENTATION: Each tablet contains 50 mg of Vildagliptin INDICATIONS: For the treatment of type 2 diabetes mellitus in adults: i) As monotherapy in patients inadequately controlled by diet and exercise
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationFencino patch (5) 2. Check the practice has agreed to the protocol and a signed copy is in place.
Switch protocol: Fentanyl/Durogesic patches to Fencino /Matrifen /Mezolar brand switch Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols are produced by the
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationSTEP 3: Add or Substitute with one of
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationSeretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD.
Seretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD. Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians These protocols are produced by the NY&AWC MM team hosted
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationScottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More informationOral Treatments for Type 2 Diabetes. Prescribing Support Pharmacist
Oral Treatments for Type 2 Diabetes Prescribing Support Pharmacist Learning Outcomes Familiar with classes of oral hypoglycaemic agents (OHAs) used in controlling blood glucose levels When to use each
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes
National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationArrange 3 Monthly Review Re-enforce LIFESTYLE advice and check DRUG COMPLIANCE at each visit Target HbA1c < 53mmol/mol
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationthe person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and
Exenatide (Byetta) and Liraglutide (Victoza) prescribing guidance: Notes for initiation in primary care These incretin mimetics are given by subcutaneous injection once or twice daily. They have similar
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationDiabetes Prescribing Guidelines for the Glycaemia management of Adults with Type 2 Diabetes
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More informationTechnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418
Dapagliflozin in triple therapy for treating type 2 diabetes Technology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418 NICE 2018. All rights reserved. Subject to Notice of rights
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationDenosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures
APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,
More informationDiabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust
Diabetes Update: Keeping patients safe Victoria Ruszala MFRPSII North Bristol NHS Trust Declaration of Interests I have received funding from the following companies for providing education sessions, attending
More informationAll patients put on this combination must have been seen by a dietitian and made appropriate efforts to lose weight
Shared Care Protocol: Addition of a glucagonlike peptide-1 (GLP-1) analogues (exenatide or liraglutide) to patients already on insulin who have poorly controlled type 2 diabetes All patients put on this
More informationSIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION
SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION DR ROSE ZHAO-WEI TING ( 丁昭慧醫生 ) MBBS (HK), MRCP (UK), FHKCP, FHKAM (MEDICINE) Specialist in Endocrinology, Diabetes and Metabolism
More informationNHS Dumfries & Galloway Ferrous Salt Review Protocol November 09
Title of Project: NHS Dumfries & Galloway Ferrous Salt Review Protocol November 09 1 Reason for the review Choice of iron preparation is based on cost and incidence of side effects (BNF). There is little
More informationVolume 8; Number 10 May 2014
Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationType 2 Diabetes Therapies and Management: An Educational Toolkit
University Hospitals of Leicester, Department of Diabetes and Leicester Diabetes Centre: Type 2 Diabetes Therapies and Management: An Educational Toolkit Acknowledgements This document is designed to enable
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationDPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes
THERAPY REVIEW DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes STEVE CHAPLIN SPL DPP-4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixeddose
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPractice Name. Audit Undertaken By and Job Title. Date of Audit
Pregabalin Audit Template This template can be used to document the Pregabalin audit undertaken by practices as part of the Incentive Scheme. It has been produced to provide practices with a guide but
More informationMerck & Co, Inc. Announced Approval of JANUVIA TM (INN: sitagliptin), a new oral treatment of diabetes, by the US FDA
October 23, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Phone: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Phone: +81-3-6272-1001 Merck & Co, Inc. Announced Approval of JANUVIA
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Management of Type 2 Diabetes in adults
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) in adults Key messages: Education and lifestyle advice are fundamental to patient management, as is overall consideration to the patient s risk of macrovascular
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationMedicines Optimisation Team Standard Operating Procedure for Audit: High Dose Inhaled Corticosteroids
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More information667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY
667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY Contents Introduction... 1 Patient Education for People with Type 2 Diabetes... 2 Dietary Advice for People with Type 2 Diabetes...
More informationDorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA )
INDICATION SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA ) Eplerenone is an aldosterone antagonist licensed to be used in addition to standard therapy including beta-blockers, to reduce the
More informationVolume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)
Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) The purpose of this special edition of the PACE Bulletin is to summarize the
More informationBNSSG Shared Care Guidance Please complete all sections
NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationDiabetes, Type 2 Management
CLINICAL GUIDELINE Diabetes, Type 2 Management A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. Clinical judgement should be exercised on the applicability
More informationMedicines Optimisation Prescribing Audit: Long acting muscarinic antagonist (LAMA ) review
Medicines Optimisation Prescribing Audit: Long acting muscarinic antagonist (LAMA ) review Aim To identify all patients prescribed long acting muscarinic antagonists (LAMAs) and where clinically appropriate
More informationNew Medicine Assessment
New Medicine Assessment Insulin degludec plus liraglutide (Xultophy ) 100 units/ml insulin degludec plus 3.6 mg/ml liraglutide solution for injection in a pre-filled pen Treatment of adults with type 2
More informationVitamin D & Type 2 DM
Vitamin D & PTH Vitamin D & Type 2 DM Enhances insulion secretion Increases insulin release Promotes β-cell survival Reduces PTH Enhances insulin sensitivity RAS blockade Antiinflammatory Harinarayan Hormones
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 29 October 2014 EUCREAS 50 mg/1000 mg, film-coated tablet B/60 (CIP: 34009 382 770 5 0) B/3 x 60 (CIP: 34009 571 766
More informationThis supplement has been developed in partnership with Takeda UK Ltd. Guidance Update
This supplement has been developed in partnership with Takeda UK Ltd cpd credits Guidance Update Diabetes NICE guidance on glycaemic control of adults with type 2 diabetes mellitus This supplement has
More informationMedia Contacts: Amy Rose Investor Contact: Graeme Bell (908) (908)
News Release FOR IMMEDIATE RELEASE Media Contacts: Amy Rose Investor Contact: Graeme Bell (908) 423-6537 (908) 423-5185 Tracy Ogden (267) 305-0960 FDA Approves Once-Daily JANUVIA, the First and Only DPP-4
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationOptimising Insulin Pen Needles
Optimising Insulin Pen Needles Following a review of insulin pen needles NHS Telford and Wrekin CCG now recommends the use of GlucoRx FinePoint Pen Needles. GlucoRx FinePoint Pen Needles are a high quality
More informationType 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options?
Patient decision aid Type 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options? nice.org.uk/guidance/ng28 Published: December 2015 About this decision
More informationImmediate Release Nifedipine Review July 2011
Title of Project: NHS Dumfries & Galloway - Clinical Safety Review Immediate Release Nifedipine Review July 2011 1 Reason for the review 2 Aim Immediate release nifedipine capsules are associated with
More informationCAMBRIDGESHIRE JOINT PRESCRIBING GROUP DECISION DOCUMENT Recommendation made by CJPG to Commissioners and Prescribers
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP DECISION DOCUMENT Recommendation made by CJPG to Commissioners and Prescribers Linagliptin (Trajenta, Boehringer Ingelheim Ltd) for the treatment of type 2 diabetes
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 29 October 2014 GALVUS 50 mg, tablet B/30 (CIP: 34009 381 951 6 3) B/60 (CIP: 34009 383 221 5 6) B/90 (CIP: 34009
More informationFrailty and Type 2 Diabetes Guidelines for clinicians
H.G. WELLS PROJECT Frailty and Type 2 Diabetes Guidelines for clinicians Victoria Ruszala victoria.ruszala@nhs.net H.G. Wells Project team Dugal T, Partington E. Kernow CCG Diabetes and Frailty Guideline
More informationOral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus You should be offering psychosocial care to all patients with diabetes, says the ADA. Here are the specific recommendations. Summary Recommendation
More informationFactsheet Sacubitril valsartan (Entresto ) for chronic heart failure with reduced ejection fraction
North Central London Joint Formulary Committee Factsheet Sacubitril valsartan (Entresto ) for chronic heart failure with reduced ejection fraction Start date: July 2016 Review date: July 2019 Document
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.19 Subject: SGLT2 Inhibitors Page: 1 of 6 Last Review Date: September 15, 2016 SGLT2 Inhibitors Description
More informationClinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures
Clinical Guidelines Management of adult patients with diabetes undergoing endoscopic s Document Detail Document type Clinical Guideline Management of adult Patients with diabetes Undergoing Document name
More informationA new model for prescribing varenicline
Pharmacist Independent Prescribers in partnership with A new model for prescribing varenicline Dear Stop Smoking Advisor You will be aware of the stop smoking drug varenicline that goes under the brand
More informationPatient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists
Patient Group Direction for the Supply of Varenicline (Champix ) This Patient Group Direction (PGD) is a specific written instruction for the supply of varenicline to groups of patients who may not be
More informationGLYXAMBI (empagliflozin-linagliptin) oral tablet
GLYXAMBI (empagliflozin-linagliptin) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationKaty Trinkley PharmD, BCACP Tiffany Goldberg Pharm D Candidate Katie Heist MD
Katy Trinkley PharmD, BCACP Tiffany Goldberg Pharm D Candidate Katie Heist MD Metformin: Only oral diabetes medication with proven benefits on cardiovascular morbidity and mortality Inexpensive medication
More informationDrug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:
More informationGLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.
GLP-1 GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4 Food intake éinsulin Gut églucose uptake Pancreas Beta cells Alpha cells
More informationmedicines_management/correspondence/pathway-for-the-managed- Access-of-FreeStyle-Libre.
Pathway for the Managed Access of FreeStyle Libre (Flash Glucose monitoring) for Adults and Children in the care of Trust Specialist Diabetes Clinics in Northern Ireland www.hscboard.hscni.net/download/publications/pharmacy_and_
More informationrequesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group
requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group Canterbury and Coastal Clinical Consortium Group Medicine Management plans 2013/14
More informationOral Treatments. SaminaAli Prescribing Support Pharmacist
Oral Treatments for Type 2 Diabetes SaminaAli Prescribing Support Pharmacist Learning Outcomes National Guidance Familiar with classes of oral hypoglycaemic agents (OHAs) used in controlling blood glucose
More informationEssential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community
E088 Essential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community Patient s name: DOB NHS Number Patient s address: Consultant Note: Shared care agreement sets out a
More informationempagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly
empagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationFasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period
Fasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period Dr Ketan Dhatariya MBBS MSc MD MS FRCP Consultant in Diabetes and Endocrinology Norfolk and Norwich
More informationDate of Review: September 2016 Date of Last Review: September 2015
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationPeri-operative management of the surgical patient with diabetes GL059
DT Peri-operative management of the surgical patient with diabetes GL059 Approval Approval Group Job Title, Chair of Committee Date Anaesthetics Clinical Governance Chair Anaesthetic governance Nov 2016
More information